Deaths | Productivity Loss (Low) | Productivity Loss (Low) | Productivity Loss (High) | ||
---|---|---|---|---|---|
All Variants | Status Quo | 137,829 | $744,276,600,000 | $1,585,033,500,000 | $2,412,007,500,000 |
Oral Vaccine Scenario 1 | 107,455 | $580,257,526,181 | $1,235,733,620,571 | $1,880,464,205,216 | |
Averted Scenario 1 | 30,374 | $164,019,073,819 | $349,299,879,429 | $531,543,294,784 | |
Oral Vaccine Scenario 2 | 100,729 | $543,934,686,154 | $1,158,379,424,216 | $1,762,751,297,721 | |
Averted Scenario 2 | 37,100 | $200,341,913,846 | $426,654,075,784 | $649,256,202,279 | |
Omicron | Status Quo | 112,322 | $606,536,502,230 | $1,291,698,106,600 | $1,965,627,553,522 |
Oral Vaccine Scenario 1 | 86,612 | $467,707,425,230 | $996,043,590,768 | $1,515,718,507,691 | |
Averted Scenario 1 | 25,709 | $138,829,076,999 | $295,654,515,832 | $449,909,045,831 | |
Oral Vaccine Scenario 2 | 81,118 | $438,038,940,274 | $932,860,706,138 | $1,419,570,639,775 | |
Averted Scenario 2 | 31,203 | $168,497,561,956 | $358,837,400,462 | $546,056,913,747 |